Abstract: Crystalline form, Form T1H1.5-4, of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl -1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (Compound (I)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising Form T1H1.5-4 of Compound (I) as well as a method of using the Form T1H1.5-4 of Compound for the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.

Abstract: The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway [Formula should be inserted here] wherein R1, R2, R3, R4 and R5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.

Abstract: Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I: wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.

Abstract: A spherical morphology of the high explosive tetranitroglycoluril (TNGU) has been discovered. This new morphology exhibits approximately a twofold improvement in the response of the material to impact, more than a one and a half fold improvement in friction and the same high resistance to electrostatic discharge over non-spherical TNGU produced by other methods.

Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.

Abstract: The disclosure is directed to diboron compounds, related methods of making, and related intermediate boron and diboron compounds used to make the same. The diboron compounds can be used as reagents to prepare chemical intermediates that are used in pharmaceutical, agrochemical, and specialty electronics industries. The disclosed processes and compounds provide simplified synthetic paths that significantly reduce steps, improve scalability, and minimize costs for producing the diboron reagents.

Abstract: Discloses is a process for preparation of a compound of formula 11, or a derivative thereof, wherein PG1 is an alcohol protecting group. Also, disclosed are intermediates and processes for their preparation. The compound of formula 11 can be useful in the preparation of halinchondrin analogs.

Abstract: The invention relates to isocyanate derived organosilanes and the use thereof. The isocyanate derived organosilanes can be reacted with inorganic substrates, such as oxide particles, to result in a surface modified inorganic substrate.

Abstract: In one aspect, the invention relates to compounds having the formula X: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

Abstract: A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification): The method can be used to treat cancer and myocardial infarction.

Abstract: Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B: or a pharmaceutically acceptable salt, tautomer or hydrate thereof, where X2 is a bond or linker, X3 is bond or —PO4—, and X1, R1, R2, R3, and n are described herein. Also provided in some embodiments are methods for making and using such compounds and compositions.

Abstract: The present invention relates to novel Ruthenium-based complex compounds which represent viable catalysts, in particular for all sorts of metathesis reactions. Such complex compounds can be prepared by a novel, very favourable and cost efficient method which includes the introduction of an alkylidene ligand into the complex by using vinyl sulfides or vinyl ethers.

Abstract: The invention relates to a compound of the structural formula or a hydrate or an isotope thereof. The invention also relates to a preparation method thereof and methods of providing dietary organoselenium, inactivating an enzyme, modulating the activity of a protein (e.g., methyltransferase) or nucleic acid, identifying a methyltransferase that reacts with compound, and oxidizing a methyltransferase-reactive substrate.

Abstract: The invention also relates to compounds, which are useful for intra-molecular fluorescence resonance energy transfer (FRET), comprising the oxidized form of a carbaNADH-based first fluorophore and a second fluorophore that is excitable at a wave-length of between 445 to 540 nm and that has an emission maximum of greater than 560 nm, and methods, kits and compositions related thereto.

Abstract: The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal, of protein, fragments without adversely affecting the yield of the desired protein product.

Abstract: A general method and recombinant nucleic acid sequences, by means which the method selects a recombinant protein containing an FHA domain for binding a target molecule from a library proteins with a high-throughput method of creating protein variations within the FHA domain in non-conserved or non-structural sequences of the FHA scaffold, and the library may also be in the form of a phagemid or phage library wherein the ALP nucleic acid sequence is inserted into a vector capable of allowing the vector and expressed ALP protein from being virally packaged, and the recombinant nucleic acid sequences which are randomly mutated at varying non-conserved or non-structural FHA domain sequences.

Abstract: This invention relates to protein structures, to methods of producing those protein structures, and to peptides used in the formation of the protein structures.

Abstract: A peptide domain necessary for an interaction between an envelope of a virus belonging to an HERV-W interference group and an hASCT receptor comprises (i) an N-terminus motif having an amino acid sequence selected from the group consisting of: SEQ ID No. 1 to SEQ ID No. 29, (ii) a C-terminus motif having an amino acid sequence selected from the group consisting of: SEQ ID No. 30 to SEQ ID No. 40, and (iii) at least one motif between the N-terminus and the C-terminus, and having an amino acid sequence selected from the group consisting of: SEQ ID No. 41, SEQ ID No. 42 and SEQ ID No. 73.

Abstract: The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof.

Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.

Abstract: The present invention provides for a method of genetically modifying microorganisms to enhance resistance to ionic liquids using a yeast Major Facilitator Superfamily (MFS), or a Salmonella MFS SmvA Pump or SmvR Regulator, a Small Multidrug Resistance Family (SMR), or Saccharomyces cerevisiae YDR090C, polypeptide, host cells genetically modified in accordance with the methods, and methods of using the host cells in a reaction comprising biomass that has been pretreated with ionic liquids.

Abstract: The invention relates to neuromodulatory oligomers of the amyloid-?(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-?(1-42) proteins, the production and use thereof.

Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.

Abstract: Anti-angiogenic agents or polypeptides comprising an amino acid segment substantially similar to domain one of CD2 wherein the polypeptide has a ?-sheet formed by two segments. Methods of using such agents and polypeptide are also included.

Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.

Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.

Abstract: The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100P monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them.

Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

Abstract: The present invention relates to methods for producing a particle comprising a polymer matrix and a protein.

Abstract: The present invention relates to novel antibodies, which combine high affinity with high potency, particularly novel antibodies against a novel epitope.

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.

Abstract: The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.

Abstract: Antagonist of the BTLA/HVEM interaction for use in therapy The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of V?9V?2 T cells.

Abstract: The present invention relates to the dosing regiment for anti-CD20 antibody to treat various diseases.

Abstract: The invention provides anti-CRTh2 antibodies and methods of using the same.

Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

Abstract: The present invention relates to stable formulations of polypeptides, e.g. immunoglobulin single variable domains, in particular immunoglobulin single variable domains directed against von Willebrand Factor (vWF). The invention provides formulations which are stable upon storage for prolonged periods of time and over a broad range of temperatures. The formulations of the invention ensure a high stability of the polypeptide, allowing multiple freeze-thaw cycles without chemical or physical deterioration, and provide stability in relation to mechanical stress, such as shake, shear or stir stress. They are suitable for pharmaceutical and diagnostic preparations and compatible with pharmaceutically acceptable diluents.

Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-C1s monoclonal antibodies. The invention further relates to the use of such anti-C1s antibodies in the detection of complement factors of the classical complement activation pathway, such as C1s. Additionally, the antibodies of this disclosure are useful for the diagnosis and treatment of disorders associated with an increased activation of the classical complement pathway, in particular autoimmune disorders and neurodegenerative diseases, including neurodegenerative diseases with synapse loss, such as Alzheimer's Disease. Methods of treatment of autoimmune and neurodegenerative diseases are also provided.

Abstract: The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against surface antigen CD3 of an immune cell; the monovalent unit has a specific binding capability against the surface antigen EpCAM of a tumor cell; the single-chain unit comprises a single-chain variable fragment ScFv fused with an Fc fragment; and the monovalent unit comprises a light chain and heavy chain pair. The present invention also provides a preparation method of the bispecific antibody and pharmaceutical use of these antibodies.

Abstract: A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.

Abstract: Catalyst component for the polymerization of olefins comprising Mg, Ti and an electron donor of formula (I) In which X and Y are selected from, R1, and —OR1 and —NR2, B is oxygen or sulphur S is sulphur, R1 is selected from C1-C15 hydrocarbon groups, optionally contain a heteroatom selected from halogen, P, S, N, O and Si, which can be fused together to form one or more cycles, R is hydrogen or R1 and A is a bivalent bridging group with chain length between the two bridging bonds being 1-10 atoms.

Abstract: The present invention pertains a fluoropolymer [polymer (F)] comprising: —recurring units derived from at least one ethylenically unsaturated fluorinated monomer [monomer (FM)]; —from 5% to 60% by moles [with respect to the total moles of recurring units of polymer (F)] of recurring units derived at least one ethylenically unsaturated fluorinated monomer containing at least one —SO2F functional group [monomer (IO)]; and —from 0.01% to 10% by moles [with respect to the total moles of recurring units of polymer (F)] of recurring units derived from at least one monomer comprising an azide group [monomer (Az)], to a process for its manufacture, to a cross-linkable composition comprising the same, to a process for cross-linking the same and to articles comprising the cross-linked polymer.

Abstract: Poly(ethylene tetrafluoroethylene) (ETFE) polymers having an average molecular weight of at least 300,000 g/mol and a melt enthalpy of at least 57 J/g are provided. The ETFE polymer may include at least one additional comonomer. The ETFE polymer is used to form a porous tape or membrane that has a node and fibril structure. A porous ETFE tape may be formed by lubricating the ETFE polymer and subjecting the lubricated polymer to pressure at a temperature below the melting point of the ETFE polymer. Optionally, the ETFE tape may be expanded at a temperature below the melting temperature of the ETFE polymer to form an expanded ETFE membrane. Alternatively, the ETFE polymer may subjected to heat and pressure without the addition of a lubricant to form a dense preform. The dense preform may be subsequently slit in a length direction and stretched to form a dense ETFE fiber.

Abstract: Acrylic polyols comprising hydroxy functional acrylic copolymers/resin involving an acrylic backbone having modified castor oil sourced hydroxyl functionalities and synthesized by co-reacting modified hydroxy functional Castor Oil with variety of acrylic monomers, styrene or its derivatives and optionally hydroxyalkyl acrylates/methacrylates and ethylenic monomer through solution polymerization in presence of an initiator. The hydroxyl functionality is solely or partially imparted through renewable Castor Oil wherein the resins were synthesized at upto 100% solids and at hydroxyl values ranging from 25-150 (mg KOH/gm). The synthesized resins when cured with suitable polyisocyanates or amino resin cross-linkers provided tough, glossy and chemical & weather resistant coatings.

Abstract: The invention provides an actinically-polymerizable amphiphilic polysiloxane which comprises a polysiloxane polymer chain comprising a polylsiloxane segments comprising at least one siloxane unit having a low molecular weight hydrophilic polymer chain connected with a silicone atom of the siloxane unit, and (meth)acrylamido groups each covalently bonded to one of the ends of the polysiloxane polymer chain and/or to the end of one of low molecular weight hydrophilic polymer chains each connected with one silicone atom. The present invention is also related to a polymer, an actinically-crosslinkable silicone-containing prepolymer, a silicone hydrogel polymeric material, or a silicone hydrogel contact lens, which comprises repeating units derived from an actinically-polymerizable amphiphilic polysiloxane of the invention.

Abstract: Method for preparing a ceramic-polymer nanocomposite is provided. The method includes providing a polymer comprising radicals on a surface thereof; contacting the polymer with a functionalizing agent to form a functionalized polymer; and either (i) grafting a cross-linking agent onto the functionalized polymer to form a graft copolymer, and attaching ceramic nanostructures to the graft copolymer to form a ceramic-polymer nanocomposite, or (ii) grafting a cross-linking agent onto ceramic nanostructures to form modified ceramic nanostructures, and attaching the modified ceramic nanostructures to the functionalized polymer to form a ceramic-polymer nanocomposite. A ceramic-polymer nanocomposite and use of the ceramic-polymer nanocomposite are also provided.

Abstract: The present invention relates to a liquid (meth)acrylic syrup, its method of polymerization and article obtained thereof. In particular the present invention deals with a liquid (meth)acrylic syrup comprising an initiation system for polymerization at low temperature. More particularly the present invention relates to a liquid (meth)acrylic syrup comprising an initiator system for polymerization at low temperature, said initiating system comprises at least one accelerator, at least one organic aldehyde, at least one peracid and at least one liquid peroxy compound; an impregnation process for a fibrous substrate, the liquid (meth)acrylic syrup for implementing this process, and the obtained impregnated fibrous substrate. The impregnated fibrous substrate is suitable for manufacturing mechanical or structured parts or articles.